Johnson & Johnson (NYSE:JNJ) Price Target Raised to $282.00

Johnson & Johnson (NYSE:JNJ) had its price target hoisted by Wells Fargo & Company from $272.00 to $282.00 in a research note published on Monday, MarketBeat reports. They currently have an overweight rating on the stock.

JNJ has been the subject of several other reports. Royal Bank Of Canada upped their target price on Johnson & Johnson from $265.00 to $287.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $284.00 to $294.00 and gave the company an “overweight” rating in a research note on Thursday, July 16th. Bank of America upped their price objective on shares of Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a research report on Friday, July 10th. Barclays increased their price objective on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, April 15th. Finally, Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $267.48.

Johnson & Johnson Trading Up 1.1%

JNJ stock opened at $257.77 on Monday. Johnson & Johnson has a 52-week low of $169.68 and a 52-week high of $274.90. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The firm has a market cap of $621.21 billion, a P/E ratio of 29.87, a PEG ratio of 2.42 and a beta of 0.24. The company’s 50-day simple moving average is $247.27 and its 200-day simple moving average is $239.32.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.Johnson & Johnson’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 11.69 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s payout ratio is 62.11%.

Insiders Place Their Bets

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.16% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Silver Coast Investments LLC boosted its stake in Johnson & Johnson by 3.8% during the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock valued at $271,000 after purchasing an additional 39 shares during the period. Townsend Asset Management Corp NC ADV boosted its position in shares of Johnson & Johnson by 0.6% in the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock valued at $1,630,000 after acquiring an additional 39 shares during the period. Sierra Capital LLC boosted its position in shares of Johnson & Johnson by 0.5% in the fourth quarter. Sierra Capital LLC now owns 8,144 shares of the company’s stock valued at $1,685,000 after acquiring an additional 41 shares during the period. Beaird Harris Wealth Management LLC grew its stake in shares of Johnson & Johnson by 1.8% in the fourth quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company’s stock worth $501,000 after acquiring an additional 42 shares during the last quarter. Finally, Ballast Advisors LLC increased its position in Johnson & Johnson by 1.2% during the first quarter. Ballast Advisors LLC now owns 3,598 shares of the company’s stock worth $879,000 after acquiring an additional 42 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA clearance expands J&J’s growth opportunities. The FDA authorized Johnson & Johnson’s OTTAVA robotic surgery system, marking the company’s entry into surgical robotics. Investors may view the platform as a long-term medical-device growth driver and a way to diversify beyond pharmaceuticals. Johnson & Johnson Gets FDA Nod for OTTAVA
• Positive Sentiment: Analysts continue to support JNJ’s outlook. Wells Fargo reportedly expects the stock to rise, while other market commentary identifies Johnson & Johnson as an attractive blue-chip and dependable dividend stock. The company’s latest quarter also showed earnings and revenue exceeding estimates, with full-year 2026 earnings guidance maintained at $11.60-$11.75 per share. Wells Fargo Analyst Expects Johnson & Johnson Stock to Rise
• Positive Sentiment: Dividend appeal is supporting defensive demand. JNJ is being highlighted alongside other Dividend Aristocrats for dependable income. Its large scale, 21.48% net margin, 32.42% return on equity and low-beta profile may appeal to investors seeking stability while broader equity valuations remain elevated. Strong Buy Dividend Aristocrat Stocks
• Neutral Sentiment: Leadership transition adds a near-term watchpoint. Innovative Medicine chairman Jennifer Taubert will retire after more than two decades at J&J, with Tom Cavanaugh set to succeed her in September. Taubert helped build the segment into a business generating more than $60 billion in annual revenue, making execution under the new leader important for investors. Johnson & Johnson Leadership Change

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.